See more : Superior Plus Corp. (SPB.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Esperion Therapeutics, Inc. (ESPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Esperion Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Brinno Incorporated (7402.TWO) Income Statement Analysis – Financial Results
- Bukit Jalil Global Acquisition 1 Ltd (BUJAW) Income Statement Analysis – Financial Results
- Pan Pacific International Holdings Corporation (7532.T) Income Statement Analysis – Financial Results
- DH Enchantment Inc. (ENMI) Income Statement Analysis – Financial Results
- PGS Software S.A. (PSW.WA) Income Statement Analysis – Financial Results
Esperion Therapeutics, Inc. (ESPR)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.esperion.com
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.33M | 75.48M | 78.45M | 227.55M | 148.36M | 184.47M | 0.00 | 0.00 | 0.00 | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 |
| Cost of Revenue | 43.27M | 26.97M | 14.22M | 2.39M | 175.61M | 265.00K | 258.00K | 252.00K | 236.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 786.00K | 683.22K |
| Gross Profit | 73.07M | 48.51M | 64.23M | 225.16M | -27.25M | 184.21M | -258.00K | -252.00K | -236.00K | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | -784.00K | -683.22K |
| Gross Profit Ratio | 62.81% | 64.27% | 81.88% | 98.95% | -18.36% | 99.86% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -39,200.00% | 0.00% |
| Research & Development | 86.11M | 118.93M | 105.98M | 146.94M | 175.61M | 171.49M | 147.60M | 57.87M | 29.80M | 25.30M | 16.01M | 8.00M | 7.81M | 21.99M | 21.45M | 21.79M | 8.48M |
| General & Administrative | 126.92M | 97.78M | 171.29M | 180.32M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 15.60M | 11.30M | 13.70M | 19.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 142.52M | 109.08M | 184.99M | 199.62M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 5.96M | 5.02M | 2.95M | 2.52M |
| Other Expenses | 0.00 | 2.65M | 3.98M | 515.00K | 4.06M | 2.78M | 2.19M | 1.55M | 776.00K | 119.00K | 194.01K | -83.65K | -75.81K | 0.00 | 0.00 | 5.00M | 3.20M |
| Operating Expenses | 228.63M | 228.01M | 290.96M | 346.55M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 26.79M | 11.69M |
| Cost & Expenses | 271.90M | 254.98M | 305.18M | 348.94M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 27.57M | 12.37M |
| Interest Income | 0.00 | 2.60M | 112.00K | 600.00K | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.98M | 56.81M | 46.35M | 22.67M | 8.12M | 100.00K | 198.00K | 376.00K | 520.00K | 270.00K | 936.58K | 1.49M | 577.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 164.00K | 500.00K | 612.00K | 547.00K | 319.00K | 265.00K | 258.00K | 252.00K | 236.00K | 160.00K | 70.55K | 139.43K | 178.47K | -1.29M | -2.01M | -2.05M | -683.22K |
| EBITDA | -150.11M | -176.35M | -222.14M | -120.33M | -88.73M | -204.32M | -166.53M | -74.35M | -49.03M | -36.06M | -22.69M | -10.12M | -10.06M | -27.22M | -26.80M | -25.52M | -11.69M |
| EBITDA Ratio | -129.03% | -234.31% | -283.96% | -53.12% | -60.02% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.45% | 0.00% | 0.00% | 0.00% | 0.00% | -1,086,150.00% | 0.00% |
| Operating Income | -155.56M | -179.50M | -226.73M | -121.40M | -93.10M | -204.59M | -168.98M | -76.15M | -50.04M | -36.22M | -22.76M | -10.20M | -10.16M | -27.95M | -27.32M | -27.57M | -12.37M |
| Operating Income Ratio | -133.72% | -237.83% | -289.02% | -53.35% | -62.75% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.46% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,600.00% | 0.00% |
| Total Other Income/Expenses | -53.69M | -54.16M | -42.38M | -22.16M | -4.06M | 2.78M | 1.99M | 1.17M | 256.00K | -151.00K | -3.33M | -1.54M | -652.97K | -780.00K | 2.39M | -3.80M | 0.00 |
| Income Before Tax | -209.25M | -233.66M | -269.11M | -143.55M | -97.17M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -31.37M | 0.00 |
| Income Before Tax Ratio | -179.87% | -309.58% | -343.04% | -63.09% | -65.49% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,568,550.00% | 0.00% |
| Income Tax Expense | 0.00 | 54.16M | 49.72M | 22.64M | 11.86M | 2.88M | 2.13M | 1.67M | 1.06M | 229.00K | 1.13M | 1.40M | 501.34K | 2.07M | 468.00K | 4.10M | -331.84K |
| Net Income | -209.25M | -287.82M | -318.82M | -166.19M | -109.02M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -27.58M | -10.67M |
| Net Income Ratio | -179.87% | -381.34% | -406.42% | -73.04% | -73.48% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,800.00% | 0.00% |
| EPS | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.71 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| EPS Diluted | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.70 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| Weighted Avg Shares Out | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.29M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
| Weighted Avg Shares Out (Dil) | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.34M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
Esperion Reports Second Quarter 2023 Financial Results
– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for Expanded Indications in the U.S. and...
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
ANN ARBOR, Mich., July 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the BTIG Virtual Biotechnology Conference 2023. Ben Halladay, Chief Financial Officer, will participate in a fireside chat on Monday, August 7, 2023 at...
Esperion to Report Second Quarter 2023 Financial Results on August 1
ANN ARBOR, Mich., July 17, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results before the market opens on Tuesday, August 1, 2023.
Esperion to Report Second Quarter 2023 Financial Results on August 1
ANN ARBOR, Mich., July 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results before the market opens on Tuesday, August 1, 2023.
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2023, in Arlington, TX.
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the application was filed...
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary prevention population, including 27% reduction in all-cause mortality –
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists' (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed in the CTT meta-analyses Cardiovascular risk reduction with bempedoic acid shown via the...
Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion to Present New Key Science at the American Diabetes Association's 83rd Scientific Sessions 2023
ANN ARBOR, Mich., June 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of key late breaking sessions at the American Diabetes Association's 83rd Scientific Sessions taking place on June 23-26, 2023, in San Diego, CA.
Source: https://incomestatements.info
Category: Stock Reports